Condition: Pancreatic Cancer · Sponsor: Akeso
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.
This description comes directly from the study's public registry record.
Zhifang Yao, MD · +86-0760-89873999 · clinicaltrials@akesobio.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science And Technology | Wuhan, Hubei, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Shanghai Changhai Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Zhejiang Provincial People's hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05859750